Document 0882
 DOCN  M9540882
 TI    CD4+ counts before and after switching to monoclonal high-purity factor
       VIII concentrate in HIV-infected haemophilic patients.
 DT    9504
 AU    Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C; Haemophilia
       Centre, Royal Free Hospital and School of Medicine,; London, UK.
 SO    Thromb Haemost. 1994 Aug;72(2):214-7. Unique Identifier : AIDSLINE
       MED/95133023
 AB    Allogenic proteins that contaminate intermediate purity clotting factor
       concentrates may activate the immune system of HIV-infected haemophilic
       patients. In 37 haemophilic patients infected with HIV who had
       originally been treated with intermediate purity factor VIII concentrate
       and then changed to monoclonally-purified high purity factor VIII
       concentrate the rates of CD4+ decline (10(9)/l per year) were 0.06
       before and 0.02 after a switch to high purity products (p = 0.01). The
       median follow-up of patients after the switch to high purity products
       was 1.7 years (range 0.2 to 3 years). This significant change in the
       rate of CD4 decline was independent of the starting CD4 count, age and
       antiretroviral therapy. This result is consistent with those from
       randomised trials of the introduction of high-purity concentrate. Given
       the strong association between the CD4+ count and survival, treatment
       with high purity rather than intermediate purity clotting factor
       concentrate may confer a survival benefit for HIV-infected haemophilic
       patients.
 DE    Adolescence  Adult  Aged  AIDS-Related Opportunistic
       Infections/PREVENTION & CONTROL  Child  Child, Preschool  Cohort Studies
       *CD4 Lymphocyte Count  Disease Progression  Factor VIII/ISOLATION &
       PURIF/*THERAPEUTIC USE  Fluconazole/THERAPEUTIC USE
       Hemophilia/*BLOOD/COMPLICATIONS/THERAPY  Human  HIV
       Infections/*BLOOD/COMPLICATIONS/DRUG THERAPY  Male  Middle Age
       Pentamidine/THERAPEUTIC USE  Support, Non-U.S. Gov't
       Trimethoprim-Sulfamethoxazole Combination/THERAPEUTIC USE
       Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).